Skip to main content

Heterotopic Ossification (HO)

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

ashibio
ashibioCA - Burlingame
1 program
1
AndecaliximabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT07024407Recruiting10Est. Jan 2026

Trial Timeline

Clinical trial activity over time

2025
2026
ashibioAndecaliximab

Clinical Trials (1)

Total enrollment: 10 patients across 1 trials

NCT07024407ashibioAndecaliximab

A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.

Start: May 2025Est. completion: Jan 202610 patients
Phase 1/2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 10 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.